ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Aktis Oncology Inc

Aktis Oncology Inc (AKTS)

24,09
0,56
(2,38%)
Geschlossen 19 Juni 10:00PM
24,01
-0,08
(-0,33%)
Nach Börsenschluss: 1:56AM

Aktis Oncology Inc (AKTS) Aktie

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Wichtige Statistiken und Details

Current Price
24,01
( 2,04% )
Gebot
24,52
Fragen
28,00
Volumen
552.173
23,38 Tagesbereich 24,82
0,0372 52-Wochen-Bereich 25,26
Marktkapitalisierung
Handelsende
23,53
Handelsbeginn
24,41
Letzte Trade
3
@
23.8
Letzter Handelszeitpunkt
Finanzvolumen
US$ 13.313.698
VWAP
24,1115
Durchschnittliches Volumen (3 Mio.)
US$ 323.685
Ausgegebene Aktien
55.277.447
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-4,18
Gewinn pro Aktie (EPS)
-5,25
Erlöse (LTM)
8,28M
Nettogewinn (LTM)
-67,07M

Über Aktis Oncology Inc

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company’s lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is... Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company’s lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts. Mehr anzeigen

Sektor
Technology
Branche
Hardware & Equipment
Hauptsitz
Boston, United States
Gegründet
2026
Aktis Oncology Inc is listed in the Technology sector of the NASDAQ with ticker AKTS. The last closing price for Aktis Oncology was US$23,53. Over the last year, Aktis Oncology shares have traded in a share price range of US$ 0,0372 to US$ 25,26.

Aktis Oncology currently has 55.277.447 shares in issue. The market capitalisation of Aktis Oncology is US$1,33 billion. Aktis Oncology has a price to earnings ratio (PE ratio) of -4.18.

AKTS Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
15.3328.533190578218.6825.2618.2550891522.03869875CS
45.2327.848775292918.7825.2618.2525075120.95530989CS
125.7931.778265642218.2225.2614.7225558419.20078231CS
2623.972864443.01075270.037225.260.037226614619.22941781CS
5223.972864443.01075270.037225.260.037213148219.22941781CS
15620.78643.3436532513.2325.260.03339059790.40455667CS
26013.48128.01519468210.5325.260.03325502790.8078876CS

AKTS - Frequently Asked Questions (FAQ)

What is the current Aktis Oncology Inc share price?
The current share price of Aktis Oncology Inc is US$ 24,01
How many Aktis Oncology Inc shares are in issue?
Aktis Oncology Inc has 55.277.447 shares in issue
What is the market cap of Aktis Oncology Inc?
The market capitalisation of Aktis Oncology Inc is USD 1,33B
What is the 1 year trading range for Aktis Oncology Inc share price?
Aktis Oncology Inc has traded in the range of US$ 0,0372 to US$ 25,26 during the past year
What is the PE ratio of Aktis Oncology Inc?
The price to earnings ratio of Aktis Oncology Inc is -4,18
What is the cash to sales ratio of Aktis Oncology Inc?
The cash to sales ratio of Aktis Oncology Inc is 146,46
What is the registered address of Aktis Oncology Inc?
The registered address for Aktis Oncology Inc is 17 Drydock Avenue, Boston, Massachusetts, 02210
What is the Aktis Oncology Inc website address?
The website address for Aktis Oncology Inc is www.aktisoncology.com
Which industry sector does Aktis Oncology Inc operate in?
Aktis Oncology Inc operates in the Hardware & Equipment sector

AKTS Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen